Leerink on Medline Inc (MDLN): 'view the recent stock weakness as primarily timing-related rather than indicative of any structural business deterioration'
Tweet Send to a Friend
Leerink analyst Michael Cherny reiterated an Outperform rating and $52.00 price target on Medline Inc (NASDAQ: MDLN).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
